An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy with Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

Treatment for Refractory Schizophrenia in Adults

Mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score after 8 weeks of randomized treatment

Percent change from baseline in PANSS total score after 8 weeks of treatment, Percentage of subjects with 20% or more reduction from baseline in PANSS total score after 8 weeks of treatment, Percent change in PANSS sub-scales and Marder PANSS factor scores, Percent change in Personal and Social Performance (PSP) scale, Percent change in Schizophrenia Quality of Life Scale (SQLS), Percent change in Clinical Global Impression-Severity (CGI-S) and -improvement (CGI-I), Percent change in Hamilton Depression Rating Scale (HDRS), Serum pharmacokinetic evaluations

No related papers found yet.

Poland